Globalstar, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Globalstar, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $31.84M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $38.61M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $31.19M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $30.08M | Feb 28, 2020 |
| FY2019 | Dec 31, 2018 | $31.95M | Feb 28, 2020 |
| FY2019 | Sep 30, 2018 | $35.69M | Feb 28, 2020 |
| FY2019 | Jun 30, 2018 | $33.73M | Feb 28, 2020 |
| FY2019 | Mar 31, 2018 | $28.75M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $29.43M | Feb 28, 2019 |
| FY2018 | Sep 30, 2017 | $30.46M | Feb 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $272.99M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $250.35M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $223.81M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $148.50M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $124.30M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $128.49M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $131.72M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $130.11M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $112.66M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $96.86M | Feb 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.65M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($63.16M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($24.72M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($256.92M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($112.63M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($109.64M) | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | ($37.75M) | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $21.11M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $6.19M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $25.77M | Feb 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($949.0K) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($165.0K) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($221.03M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($65.50M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($59.16M) | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | ($17.05M) | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | ($12.01M) | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | ($16.66M) | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | ($18.33M) | Feb 28, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.10M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.50M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.40M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $500.0K | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.90M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $3.20M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $2.70M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $3.80M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $2.10M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $43.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $43.46M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $33.35M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $34.63M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $41.74M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $45.23M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $55.44M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $38.76M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $40.56M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $621.65M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $439.19M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $74.34M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $63.80M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $131.88M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $22.22M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $3.05M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $5.92M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $13.86M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $8.81M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $4.59M | Feb 28, 2020 |
| FY2019 | Dec 31, 2018 | $7.35M | Feb 28, 2020 |
| FY2019 | Dec 31, 2017 | $5.53M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $9.39M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $5.52M | Feb 23, 2018 |
| FY2016 | Dec 31, 2014 | $3.28M | Feb 23, 2017 |
| FY2015 | Dec 31, 2013 | $1.65M | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $781.0K | Mar 2, 2015 |
| FY2013 | Dec 31, 2011 | $2.59M | Mar 11, 2014 |
| FY2012 | Dec 31, 2010 | $7.29M | Mar 15, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.33B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.71B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $924.31M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $738.47M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $814.11M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $888.09M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $965.59M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $1.05B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $1.13B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.13B | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.97B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.35B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $545.33M | Feb 28, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $355.73M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $358.88M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $378.98M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $314.77M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $365.43M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $423.07M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $407.34M | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $358.95M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $291.22M | Mar 4, 2021 |
| FY2019 | Dec 31, 2016 | $161.82M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.60M | Feb 27, 2026 |
| FY2024 | Dec 31, 2024 | $30.60M | Feb 28, 2025 |
| FY2023 | Dec 31, 2023 | $30.60M | Feb 29, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.14B) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($2.13B) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($2.06B) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($2.04B) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.78B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($1.67B) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($1.56B) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($1.57B) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($1.57B) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($1.48B) | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $447.47M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $391.16M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $56.74M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $32.08M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $14.30M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $13.33M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $7.61M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $15.21M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $41.64M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $10.23M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $483.79M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $511.42M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $360.30M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $191.69M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $237.93M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $385.41M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $464.18M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $463.45M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $513.87M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $576.28M | Feb 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 28, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 28, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 11, 2025 | 126.44M | Feb 27, 2026 |
| FY2025 | Feb 10, 2025 | 1.90B | Feb 27, 2026 |